COMMUNIQUÉS West-GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2024
SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
02/10/2024
VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering [...]
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2024
WALTHAM, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]
Globus Medical Launches the Next Wave of Orthopedic Trauma Solutions
02/10/2024
AUDUBON, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, announces the continued growth and expansion of its orthopedic trauma product portfolio. [...]
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2024
WALTHAM, Mass. and DUBLIN, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to [...]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2024
CHARLESTOWN, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]
Certara Completes Acquisition of Chemaxon
02/10/2024
The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., [...]
BriaCell Therapeutics Announces Closing of $5 Million Offering
02/10/2024
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 02, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that [...]
Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company
02/10/2024
Company raises $31 million through ATM, bringing cash runway into 2027 New additions to leadership in technical operations, finance and intellectual property prepare Codexis for the next phase of growth REDWOOD CITY, [...]
Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1
02/10/2024
TuHURA has extended their exclusivity and right of first offer pursuant to the terms of the agreement. Kineta and TuHURA are collaborating on the ongoing Phase 1/Phase 2 clinical trial in patients with advance solid [...]
Range Impact Announces Sale of Cannabinoid Drug Development Business
02/10/2024
CLEVELAND, OHIO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public company dedicated to improving the health and wellness of people and the planet through a [...]
Venus Concept to Release Third Quarter of Fiscal Year 2024 Financial Results on November 13, 2024
02/10/2024
TORONTO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2024 [...]
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
02/10/2024
Phase 2 trial is an adaptive designed randomized study comparing NGC-Cap to monotherapy capecitabine Results from this Phase 2 trial will evaluate NGC-Cap’s safety-efficacy profile and help to define the optimal dosage [...]
Option Care Health to Announce Third Quarter 2024 Financial Results and Host Conference Call
02/10/2024
BANNOCKBURN, Ill., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, today announced [...]
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
02/10/2024
SAN DIEGO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)- [...]
Cytokinetics to Host Investor & Analyst Day on October 16, 2024
02/10/2024
Company Leadership to Discuss Cardiac Myosin Modulation, Specialty Cardiology Programs and Commercial Launch Preparations SOUTH SAN FRANCISCO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq [...]
ALPHA PRO TECH, LTD. ANNOUNCES $1 MILLION EXPANSION OF SHARE REPURCHASE PROGRAM FOR IMMEDIATE RELEASE
02/10/2024
NOGALES, Ariz., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Alpha Pro Tech, Ltd. (NYSE American: APT) , a leading manufacturer of products designed to protect people, products and environments, including disposable protective [...]
MESA LABS DECLARES QUARTERLY DIVIDEND
02/10/2024
LAKEWOOD, Colo., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0 [...]
Doheny Eye Institute To Receive Funding from NIH Award Supporting Cerebral Small Vessel Disease Detection
02/10/2024
Yuhua Zhang, Ph.D., Principal Investigator at Doheny Eye Institute and Professor of Ophthalmology at the David Geffen School of Medicine, UCLA, will lead the development of the next generation of advanced retinal [...]

Pages